Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies.

Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D.

Clin Cancer Res. 2010 Feb 15;16(4):1256-63. doi: 10.1158/1078-0432.CCR-09-1267. Epub 2010 Feb 9.

2.

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.

Doi T, Murakami H, Ohtsu A, Fuse N, Yoshino T, Yamamoto N, Boku N, Onozawa Y, Hsu CP, Gorski KS, Friberg G, Kawaguchi T, Sasaki T.

Cancer Chemother Pharmacol. 2011 Sep;68(3):733-41. doi: 10.1007/s00280-010-1544-1. Epub 2010 Dec 16.

PMID:
21161528
3.

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL, Oza AM.

Clin Cancer Res. 2008 Jun 1;14(11):3450-5. doi: 10.1158/1078-0432.CCR-07-1416.

4.

A first-in-human study of conatumumab in adult patients with advanced solid tumors.

Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, Juan G, Hwang YC, Wong S, Hill JS, Friberg G, LoRusso PM.

Clin Cancer Res. 2010 Dec 1;16(23):5883-91. doi: 10.1158/1078-0432.CCR-10-0631. Epub 2010 Oct 14.

5.

Conatumumab: a novel monoclonal antibody against death receptor 5 for the treatment of advanced malignancies in adults.

Bajaj M, Heath EI.

Expert Opin Biol Ther. 2011 Nov;11(11):1519-24. doi: 10.1517/14712598.2011.610788. Epub 2011 Aug 31. Review.

PMID:
21877997
6.

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.

Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A.

Clin Cancer Res. 2008 May 15;14(10):3044-51. doi: 10.1158/1078-0432.CCR-07-4079.

7.

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.

Gordon MS, Sweeney CS, Mendelson DS, Eckhardt SG, Anderson A, Beaupre DM, Branstetter D, Burgess TL, Coxon A, Deng H, Kaplan-Lefko P, Leitch IM, Oliner KS, Yan L, Zhu M, Gore L.

Clin Cancer Res. 2010 Jan 15;16(2):699-710. doi: 10.1158/1078-0432.CCR-09-1365. Epub 2010 Jan 12.

8.

Conatumumab, a fully human mAb against death receptor 5 for the treatment of cancer.

Rosevear HM, Lightfoot AJ, Griffith TS.

Curr Opin Investig Drugs. 2010 Jun;11(6):688-98. Review.

PMID:
20496264
9.

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.

Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, Ashkenazi A, Jubb AM, Mendelson DS.

J Clin Oncol. 2010 Jun 10;28(17):2839-46. doi: 10.1200/JCO.2009.25.1991. Epub 2010 May 10.

PMID:
20458040
10.

Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.

Camidge DR.

Expert Opin Biol Ther. 2008 Aug;8(8):1167-76. doi: 10.1517/14712598.8.8.1167 .

PMID:
18613768
11.

Phase I study of U3-1287, a fully human anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

LoRusso P, Jänne PA, Oliveira M, Rizvi N, Malburg L, Keedy V, Yee L, Copigneaux C, Hettmann T, Wu CY, Ang A, Halim AB, Beckman RA, Beaupre D, Berlin J.

Clin Cancer Res. 2013 Jun 1;19(11):3078-87. doi: 10.1158/1078-0432.CCR-12-3051. Epub 2013 Apr 16.

12.

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.

Greco FA, Bonomi P, Crawford J, Kelly K, Oh Y, Halpern W, Lo L, Gallant G, Klein J.

Lung Cancer. 2008 Jul;61(1):82-90. doi: 10.1016/j.lungcan.2007.12.011. Epub 2008 Feb 5.

PMID:
18255187
13.

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.

14.

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer.

Trarbach T, Moehler M, Heinemann V, Köhne CH, Przyborek M, Schulz C, Sneller V, Gallant G, Kanzler S.

Br J Cancer. 2010 Feb 2;102(3):506-12. doi: 10.1038/sj.bjc.6605507. Epub 2010 Jan 12.

15.

Targeting the extrinsic apoptosis pathway in cancer.

Ashkenazi A.

Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31. doi: 10.1016/j.cytogfr.2008.04.001. Epub 2008 May 20. Review.

PMID:
18495520
16.

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, Green SJ, O'Dwyer PJ, Running KL, Huhn RD, Antonia SJ.

J Clin Oncol. 2007 Mar 1;25(7):876-83.

PMID:
17327609
17.

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, Padavic K, Hill M, Mays T, McCoy T, Fox NL, Halpern W, Corey A, Cohen RB.

J Clin Oncol. 2007 Apr 10;25(11):1390-5. Erratum in: J Clin Oncol. 2007 Oct 10;25(29):4701.

PMID:
17416859
18.

Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.

Xiang H, Reyes AE 2nd, Eppler S, Kelley S, Damico-Beyer LA.

Cancer Chemother Pharmacol. 2013 Aug;72(2):405-15. doi: 10.1007/s00280-013-2200-3. Epub 2013 Jun 16.

PMID:
23771513
19.

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I.

J Clin Oncol. 2009 Dec 1;27(34):5800-7. doi: 10.1200/JCO.2009.23.6745. Epub 2009 Sep 28.

PMID:
19786654
20.

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.

Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Lacouture ME, Langmuir VK, Lee H, Kroll S, Burris HA 3rd.

Clin Cancer Res. 2011 May 1;17(9):2997-3004. doi: 10.1158/1078-0432.CCR-10-3425. Epub 2011 Mar 17.

Supplemental Content

Support Center